NCT02283879

Human Umbilical Cord Mesenchymal Stem Cell in Cerebral Hemorrhage Sequela

Human Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Cerebral Hemorrhage

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD · Industry
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for cerebral hemorrhage sequela.

Detailed description

Human umbilical cord mesenchymal stem cells exhibit the potential to differentiate into neural cells, which have been confirmed in in vivo and in vitro experiments. There have been few clinical reports describing umbilical cord mesenchymal stem cells for treatment of cerebral hemorrhage. To investigate the effects of hUC-MSC treatment for cerebral hemorrhage sequela, 20 patients with cerebral hemorrhage will be enrolled and receive 4 times of hUC-MSC transplantation.

Conditions

• Cerebral Hemorrhage

Interventions

Type	Name	Description
BIOLOGICAL	Human umbilical cord mesenchymal stem cells	A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.

Timeline

• Start date: 2015-03-01
• Primary completion: 2016-12-01
• Completion: 2017-04-01
• First posted: 2014-11-05
• Last updated: 2016-05-24

Locations

1 site across 1 country: China